Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94%

LabNews Media LLC
2025-03-30
Aktuelles

In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years

These data were presented at the American College of Cardiology 2025 Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM).

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94%

LabNews Media LLC

Stay Connected

Unmatched reporting

Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94%

LabNews Media LLC

Ähnliche Beiträge

Abbott präsentiert starke klinische Daten zu neuen Technologien gegen Herzrhythmusstörungen

Tangieren die GOÄneu-Kürzungen im Laborbereich (Kapitel M) Forschung und Entwicklung?

Genaue Aufschlüsselung: Wer genau die Honorare aus Kapitel M „Ärztliche Laboratoriumsleistungen“ der GOÄneu erhält

Stay Connected

Unmatched reporting